Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12

References

• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:172 - 83; http://dx.doi.org/10.1038/nrc1567; PMID: 15719031
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079 - 82; http://dx.doi.org/10.1126/science.2408149; PMID: 2408149
   PubMed Web of Science ®Google Scholar
• Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98:2887 - 93; http://dx.doi.org/10.1182/blood.V98.10.2887; PMID: 11698267
   PubMed Web of Science ®Google Scholar
• Grünebach F, Mirakaj V, Muller MR, Brummendorf T, Brossart P. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res 2006; 66:5892 - 900; http://dx.doi.org/10.1158/0008-5472.CAN-05-2868; PMID: 16740729
   PubMed Web of Science ®Google Scholar
• Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101:2290 - 6; http://dx.doi.org/10.1172/JCI488; PMID: 9593785
   PubMed Web of Science ®Google Scholar
• Sun JY, Krouse RS, Forman SJ, Senitzer D, Sniecinski I, Chatterjee S, et al. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res 2002; 62:3175 - 83; PMID: 12036931
   PubMed Web of Science ®Google Scholar
• Shashidharamurthy R, Bozeman EN, Patel J, Kaur R, Meganathan J, Selvaraj P. Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Med Res Rev 2011; http://dx.doi.org/10.1002/med.20237; PMID: 21241001
   PubMed Web of Science ®Google Scholar
• Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85:2680 - 4; PMID: 7742526
   PubMed Web of Science ®Google Scholar
• Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D, et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004; 18:1656 - 61; http://dx.doi.org/10.1038/sj.leu.2403474; PMID: 15343347
   PubMed Web of Science ®Google Scholar
• Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E, et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003; 101:3560 - 7; http://dx.doi.org/10.1182/blood-2002-06-1841; PMID: 12506035
   PubMed Web of Science ®Google Scholar
• Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 1999; 162:2912 - 21; PMID: 10072541
   PubMed Web of Science ®Google Scholar
• Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, et al. Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol Immunother 2005; 54:37 - 43; http://dx.doi.org/10.1007/s00262-004-0574-0; PMID: 15693137
   PubMed Web of Science ®Google Scholar
• Rodolfo M, Colombo MP. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 1999; 19:114 - 20; http://dx.doi.org/10.1006/meth.1999.0836; PMID: 10525447
   PubMed Web of Science ®Google Scholar
• Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19:3836 - 47; PMID: 11559721
   PubMed Web of Science ®Google Scholar
• Ikezawa H. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol Pharm Bull 2002; 25:409 - 17; http://dx.doi.org/10.1248/bpb.25.409; PMID: 11995915
   PubMed Web of Science ®Google Scholar
• Ji J, Li J, Holmes LM, Burgin KE, Yu X, Wagner TE, et al. Synergistic anti-tumor effect of glycosylphosphatidylinositol-anchored IL-2 and IL-12. J Gene Med 2004; 6:777 - 85; http://dx.doi.org/10.1002/jgm.547; PMID: 15241785
   PubMed Web of Science ®Google Scholar
• McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999; 59:2433 - 7; PMID: 10344754
   PubMed Web of Science ®Google Scholar
• Nagarajan S, Selvaraj P. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 2002; 62:2869 - 74; PMID: 12019166
   PubMed Web of Science ®Google Scholar
• Zhao F, Dou J, Wang J, Chu L, Tang Q, Wang Y, et al. Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice. Immunobiology 2010; 215:89 - 100; http://dx.doi.org/10.1016/j.imbio.2009.02.003; PMID: 19457579
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289:1938 - 42; http://dx.doi.org/10.1126/science.289.5486.1938; PMID: 10988075
   PubMed Web of Science ®Google Scholar
• Osman Y, Takahashi M, Zheng Z, Koike T, Toba K, Liu A, et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 1999; 13:166 - 74; http://dx.doi.org/10.1038/sj.leu.2401311; PMID: 10025889
   PubMed Web of Science ®Google Scholar
• Schwartz J, Pinilla-Ibarz J, Yuan RR, Scheinberg DA. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin Hematol 2003; 40:87 - 96; http://dx.doi.org/10.1016/S0037-1963(03)70046-8; PMID: 12563615
   PubMed Web of Science ®Google Scholar
• Englund PT. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu Rev Biochem 1993; 62:121 - 38; http://dx.doi.org/10.1146/annurev.bi.62.070193.001005; PMID: 8352586
   PubMed Web of Science ®Google Scholar
• Bütikofer P, Malherbe T, Boschung M, Roditi I. GPI-anchored proteins: now you see 'em, now you don't. FASEB J 2001; 15:545 - 8; http://dx.doi.org/10.1096/fj.00-0415hyp; PMID: 11156970
   PubMed Web of Science ®Google Scholar
• Caras IW, Weddell GN. Signal peptide for protein secretion directing glycophospholipid membrane anchor attachment. Science 1989; 243:1196 - 8; http://dx.doi.org/10.1126/science.2466338; PMID: 2466338
   PubMed Web of Science ®Google Scholar
• van der Schoot CE, Huizinga TW, van't Veer-Korthof ET, Wijmans R, Pinkster J, von dem Borne AE. Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 1990; 76:1853 - 9; PMID: 2145990
   PubMed Web of Science ®Google Scholar
• Shi M, Su L, Hao S, Guo X, Xiang J. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor. Tumori 2005; 91:531 - 8; PMID: 16457153
   PubMed Web of Science ®Google Scholar
• Li S, Ilaria RL Jr., Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189:1399 - 412; http://dx.doi.org/10.1084/jem.189.9.1399; PMID: 10224280
   PubMed Web of Science ®Google Scholar